Understanding the role of dopamine in conditioned and unconditioned fear.


Journal

Reviews in the neurosciences
ISSN: 2191-0200
Titre abrégé: Rev Neurosci
Pays: Germany
ID NLM: 8711016

Informations de publication

Date de publication:
24 04 2019
Historique:
received: 16 03 2018
accepted: 10 06 2018
pubmed: 5 9 2018
medline: 23 8 2019
entrez: 5 9 2018
Statut: ppublish

Résumé

Pharmacological and molecular imaging studies in anxiety disorders have primarily focused on the serotonin system. In the meantime, dopamine has been known as the neurotransmitter of reward for 60 years, particularly for its action in the nervous terminals of the mesocorticolimbic system. Interest in the mediation by dopamine of the well-known brain aversion system has grown recently, particularly given recent evidence obtained on the role of D2 dopamine receptors in unconditioned fear. However, it has been established that excitation of the mesocorticolimbic pathway, originating from dopaminergic (DA) neurons from the ventral tegmental area (VTA), is relevant for the development of anxiety. Among the forebrain regions innervated by this pathway, the amygdala is an essential component of the neural circuitry of conditioned fear. Current findings indicate that the dopamine D2 receptor-signaling pathway connecting the VTA to the basolateral amygdala modulates fear and anxiety, whereas neural circuits in the midbrain tectum underlie the expression of innate fear. The A13 nucleus of the zona incerta is proposed as the origin of these DA neurons projecting to caudal structures of the brain aversion system. In this article we review data obtained in studies showing that DA receptor-mediated mechanisms on ascending or descending DA pathways play opposing roles in fear/anxiety processes. Dopamine appears to mediate conditioned fear by acting at rostral levels of the brain and regulate unconditioned fear at the midbrain level.

Identifiants

pubmed: 30179855
doi: 10.1515/revneuro-2018-0023
pii: /j/revneuro.ahead-of-print/revneuro-2018-0023/revneuro-2018-0023.xml
doi:
pii:

Substances chimiques

Dopamine VTD58H1Z2X

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

325-337

Auteurs

Marcus L Brandão (ML)

Instituto de Neurociências e Comportamento (INeC), Campus USP, Monte Alegre, Ribeirão Preto, SP, 14050-220, Brazil.
NAP-USP-Neurobiology of Emotions Research Centre (NuPNE), Ribeirão Preto Medical School of the University of São Paulo, Ribeirão Preto, SP, 14049-900, Brazil.

Norberto C Coimbra (NC)

Instituto de Neurociências e Comportamento (INeC), Campus USP, Monte Alegre, Ribeirão Preto, SP, 14050-220, Brazil.
NAP-USP-Neurobiology of Emotions Research Centre (NuPNE), Ribeirão Preto Medical School of the University of São Paulo, Ribeirão Preto, SP, 14049-900, Brazil.
Laboratory of Neuroanatomy and Neuropsychobiology, Department of Pharmacology, Ribeirão Preto Medical School of the University of São Paulo, Ribeirão Preto, SP, 14049-900, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH